Sakar Healthcare Limited has informed the Exchange about Sakar enters it s 40th agreement signed with Zydus Lifesciences to cater oncology products to GCC and other emerging markets, in parallel to building momentum on strong execution and expanding Business Opportunities

Sakar Healthcare signed its 40th agreement with Zydus Lifesciences to supply oncology products to GCC and emerging markets. The company has 23 Marketing Authorization filings in the EU with 5 MAs secured (in Bulgaria, with applications pending in Czech Republic, Croatia, and Poland). It submitted 33 site variations across major European markets including Germany, Italy, France, and the UK, with 5 approvals from EMA and MHRA covering 18 cytotoxic molecules. On the API side, 21 APIs have been developed in-house, including 16 with Written Confirmation and 2 CEP approvals. This signals a shift toward an integrated, regulatory-led business model with better supply chain control.